BIOGNOSYS
14.12.2021 16:02:08 CET | Business Wire | Press release
Biognosys, a leading developer and provider of next-generation proteomics technology and solutions, and Thermo Fisher Scientific, the world leader in serving science with innovative technologies, purchasing convenience and pharmaceutical services, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.
The agreement leverages the two companies’ complementary capabilities in mass spectrometry-based proteomics. Biognosys deploys Thermo Fisher Scientific instruments in its state-of-the-art facility for contract research services, while Thermo Fisher Scientific co-markets Biognosys software and kits with its Thermo Scientific™ instruments and workflows.
Biognosys’ Biomarker Discovery services for pharmaceuticals and diagnostics development integrate Thermo Scientific Orbitrap™ and FAIMS Pro™ instruments with Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and Spectronaut™ Data Independent Acquisition (DIA) analysis software to offer unprecedented depth, quantitative precision, and throughput for unbiased discovery. This new and improved solution searches the complete proteome to quantify up to 3,000 of the most relevant proteins in biofluids and more than 10,000 proteins in tissue biopsies.
Andreas Huhmer, PhD, Senior Director Life Sciences Research OMICS Marketing at Thermo Fisher Scientific: “Biognosys’ Biomarker Discovery solutions maximize all innovative features of the Thermo Scientific Orbitrap mass spectrometers to analyze the proteome with industry-leading depth. Their unbiased discovery approach, coupled with their state-of-the-art data analysis capabilities, unlocks possibilities for transformative biomarker discovery.”
Through the companies’ extended co-marketing agreement , laboratories with in-house proteomics facilities have access to efficient, accurate, and scalable mass spectrometry-based proteomics workflows combining Thermo Scientific mass spectrometry instruments with Biognosys’ proteomics data analysis software and kits.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys: “Our agreement with Thermo Fisher Scientific has helped to greatly advance Biognosys’ mission to give researchers a look at every angle of the proteome to unlock discoveries and transform clinical research. Our suite of software and kits uniquely complements Thermo Scientific mass spectrometry instruments and workflows to enable researchers to obtain the best possible data and insights in any proteomics application.”
Biognosys’ leading DIA software solution, Spectronaut, is compatible with Thermo Scientific Orbitrap Exploris™ 480 and Thermo Scientific™ Q Exactive™ instruments.
Biognosys’ SpectroDive™ software for automated mass spectrometry method set-up, signal processing, and analysis of targeted proteomics experiments supports the SureQuant IS-PRM targeted acquisition workflow.
The PQ500™ Reference Peptide Kit from Biognosys can quantify more than 500 proteins in human plasma/serum samples as part of the SureQuant IS-PRM workflow with the Orbitrap Exploris™ 480 mass spectrometer, delivering sensitive and accurate quantitation to drive scientific progress or clinical decision making.
Learn more about the insights that can be uncovered through the Biognosys and Thermo Fisher Scientific partnership from Lukas Reiter’s presentation, “Recent Progress in Blood Proteomics” , during the Thermo Fisher Scientific dinner workshop at ASMS 2021.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify Launches Global Air Travel Fraud Report Revealing Where Booking-Stage Pressure Is Most Concentrated22.4.2026 14:00:00 CEST | Press release
Q1 2026 analysis shows significant variation in prevented fraud rates by origin city, with higher concentrations across parts of Latin America, Africa, the Middle East, and South & Southeast Asia Accertify, a leading unified risk decisioning platform provider, today announced the release of its Global Air Travel Fraud Report: Q1 2026, a quarterly analysis examining how fraud risk in airline bookings varies by route origin across global markets. Based on more than 180 million airline booking transactions processed between January and March 2026, the report analyzes fraud rates by departure city as a proxy for route origin, offering airlines a practical view of where fraud prevention systems are intervening most frequently at the point of booking. The Q1 2026 findings show that fraud risk in airline bookings is unevenly distributed across markets, with meaningful differences emerging by region and by origin city. Routes originating in North America and Australia continue to exhibit consi
NetApp Strengthens its Collaboration with Google Cloud on Unified Google Cloud Storage for File and Block22.4.2026 14:00:00 CEST | Press release
Announced at Next ‘26, Flex Unified service for Google Cloud NetApp Volumes is now generally available NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today shared new innovations that help customers better leverage their enterprise data, by tapping into the benefits of AI with Google Cloud. Enterprises want to use their existing data for AI, but moving and managing that data across multiple environments is complex, slow, and expensive. NetApp is simplifying this with Google Cloud. With Google Cloud NetApp Volumes, customers can run enterprise applications, databases, and AI workloads in the cloud without rearchitecting or rebuilding their environments. “Customers can move their enterprise data, whether block or file, into Google Cloud NetApp Volumes easily, and once it’s there, they can use Google Cloud services, including for AI, directly on that data without needing to move or duplicate it again,” said Pravjit Tiwana, Senior Vice President and General Manager of
NetApp Partners with Google Cloud to Adopt AI-Driven Operations22.4.2026 14:00:00 CEST | Press release
Google Gemini Enterprise drives productivity for NetApp sales and product development NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced a strategic evolution in its partnership with Google Cloud, which has enabled enterprises to drive AI innovation with their own data stored in the NetApp data platform. After seeing the productivity and innovation benefits customers experienced using Gemini Enterprise integrated with their data in Google Cloud NetApp Volumes, NetApp has adopted Gemini Enterprise to help increase productivity in its internal product development and sales operations. With the adoption of Google Cloud AI technologies, NetApp is expanding its leadership in enterprise-grade AI innovation, not just enabling AI workloads but acting as an AI practitioner. NetApp customers will benefit from the AI-powered gains in productivity and innovation. “AI is an imperative for enterprise success, and NetApp is committed to leading by example,” said Césa
ExaGrid Named a Finalist for the Storage Awards 202622.4.2026 14:00:00 CEST | Press release
ExaGrid Product Line, Partner Program, and Team Nominated in 16 Categories for “The Storries XXIII” ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in 16 categories for the 23rd annual Storage Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422235829/en/ ExaGrid has become a finalist in the following categories: Storage Innovator of the Year Immutable Storage Company of the Year Storage Industry Champion – Commercial Storage Industry Champion – Marketing Channel Excellence Award AI Data Storage Innovator of the Year Cyber Resilient Storage Company of the Year Ransomware Product of the Year Data Protection Company of the Year Enterprise Backup Hardware Vendor of the Year Object Storage Vendor of the Year Storage Optimisation Compan
Samsung Biologics Union Holds First Rally, Warns of May 1 Strike22.4.2026 13:56:00 CEST | Press release
Union estimates about 2,200 participants at one-hour event outside Bio Campus 1 Samsung Biologics’ labor union held its first rally on Tuesday and said it would move ahead with a strike on May 1 if management continues to reject meaningful talks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422754766/en/ Union members gather at a rally organized by the Samsung Biologics labor union outside Bio Campus 1 in Songdo, Incheon, on April 22, ahead of a planned May 1 strike. The rally, held for about an hour outside the main gate of the company’s Bio Campus 1 in Songdo, drew about 2,200 participants, according to the union. The event marks an escalation in a labor dispute that union leaders say is no longer limited to a small number of bargaining items, but instead concerns broader questions about accountability and decision-making within the company. Park Jaesung, chair of the Samsung Biologics union, said management had faile
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom